Clinical Trials
231 trialsORCHID
Fudan University
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Intergroupe Francophone de Cancerologie Thoracique
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
ASPEN-09-03
ALX Oncology Inc.
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
CAMPFIRE
Eli Lilly and Company
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Delcath Systems Inc.
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
AZALEA
European Institute of Oncology
BRIDGE
Mario Negri Institute for Pharmacological Research
TrasTUCAN
Spanish Breast Cancer Research Group
Evolutionary Therapy for Rhabdomyosarcoma
H. Lee Moffitt Cancer Center and Research Institute
ATREZZO
SOLTI Breast Cancer Research Group
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
EORTC1616
The Netherlands Cancer Institute
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
MOCCCA
Insel Gruppe AG, University Hospital Bern
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
SAFIR02_Breast
UNICANCER
ORIENTA
Guangdong Provincial People's Hospital
SPRING
Peking University Shenzhen Hospital
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
EASOVCWDITHABC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RIGHT Choice
Novartis
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase â…¡ Clinical Trial
Henan Cancer Hospital
Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
METEORA-II
ETOP IBCSG Partners Foundation
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NORA
Spanish Lung Cancer Group
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
National Cancer Institute, Slovakia
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
University of Nebraska
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Henan Cancer Hospital
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
CHEOPS
ARCAGY/ GINECO GROUP
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
VEX
European Institute of Oncology
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
DURATION
AIO-Studien-gGmbH